Schatzberg A F
Department of Psychiatry, Stanford Medical Center, CA 94305-5548, USA.
Depress Anxiety. 1996;4(4):182-9. doi: 10.1002/(SICI)1520-6394(1996)4:4<182::AID-DA4>3.0.CO;2-H.
The selective serotonin reuptake inhibitors (SSRIs) are recognized as effective as and better tolerated than older antidepressant therapies and have become the drugs of choice in the treatment of mild to moderate depression. However, there is a clinical impression that the SSRIs are less effective than older therapies in the severely depressed patient. A limited number of trials have attempted to address this issue. This review assesses 16 controlled studies of SSRIs in severe depression. The findings from a majority of studies found the SSRIs to be superior to placebo and as effective as but better tolerated than the tricyclic antidepressants (TCAs) in severely depressed patients. Although future studies are needed to corroborate and elaborate on these data, studies still support the use of SSRIs in this patient population.
选择性5-羟色胺再摄取抑制剂（SSRI）被认为与较老的抗抑郁疗法疗效相当且耐受性更好，已成为治疗轻至中度抑郁症的首选药物。然而，临床上有一种印象，即SSRI在重度抑郁症患者中的疗效不如较老的疗法。少数试验试图解决这一问题。本综述评估了16项关于SSRI治疗重度抑郁症的对照研究。大多数研究结果发现，在重度抑郁症患者中，SSRI优于安慰剂，且与三环类抗抑郁药（TCA）疗效相当但耐受性更好。尽管需要进一步研究来证实和详细阐述这些数据，但现有研究仍支持在这一患者群体中使用SSRI。
